Eosinophils in antiviral immunity and (perhaps) a benefit of having asthma during the SARS-CoV2 pandemic

Ann Allergy Asthma Immunol. 2021 Jul;127(1):3-4. doi: 10.1016/j.anai.2021.03.017.

Authors

Ryan Eid¹, Larry Borish²

Affiliations

¹ Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.
² Department of Medicine, University of Virginia Health System, Charlottesville, Virginia; Department of Microbiology, University of Virginia Health System, Charlottesville, Virginia. Electronic address: lb4m@virginia.edu.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Antiviral Agents / therapeutic use
Asthma / epidemiology*
COVID-19 / epidemiology*
COVID-19 / immunology*
COVID-19 Drug Treatment
Eosinophils / immunology*
Humans
Risk Factors
SARS-CoV-2

Substances

Antiviral Agents

Grants and funding